(Q35828737)

10 August 2017

1 reference

title

Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease (English)

1 reference

10 August 2017

main subject

chronic myeloid leukemia

0 references

author name string

Chikashi Yoshida

series ordinal

1

1 reference

10 August 2017

Junia V Melo

series ordinal

2

1 reference

10 August 2017

publication date

1 June 2004

1 reference

International Journal of Hematology

10 August 2017

published in

1 reference

10 August 2017

volume

79

1 reference

10 August 2017

issue

5

1 reference

10 August 2017

page(s)

420-433

1 reference

In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells

10 August 2017

cites work

1 reference

12 December 2020

Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin

1 reference

12 December 2020

Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571).

1 reference

12 December 2020

1 reference

12 December 2020

Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).

1 reference

12 December 2020

Clinical significance of P-glycoprotein in multidrug resistance malignancies.

1 reference

12 December 2020

Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide

1 reference

12 December 2020

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

1 reference

12 December 2020

Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB).

1 reference

12 December 2020

The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells

1 reference

12 December 2020

Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells

1 reference

12 December 2020

TRAIL: a molecule with multiple receptors and control mechanisms

1 reference

12 December 2020

Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells

1 reference

12 December 2020

BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors

1 reference

12 December 2020

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

1 reference

12 December 2020

Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines

1 reference

12 December 2020

Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L)

1 reference

12 December 2020

The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells

1 reference

12 December 2020

BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase

1 reference

12 December 2020

A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia

1 reference

12 December 2020

Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.

1 reference

12 December 2020

Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity

1 reference

12 December 2020

STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'.

1 reference

12 December 2020

Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

1 reference

12 December 2020

1 reference

12 December 2020

Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.

1 reference

12 December 2020

Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs

1 reference

12 December 2020

Reversal of multidrug resistance in hematological malignancies

1 reference

12 December 2020

Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts

1 reference

12 December 2020

An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells

1 reference

12 December 2020

Molecular mechanisms of resistance of leukemia to imatinib mesylate

1 reference

12 December 2020

Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells

1 reference

12 December 2020

The therapeutic potential of ribozymes

1 reference

12 December 2020

Absence of N-ras mutations in myeloid and lymphoid blast crisis of chronic myeloid leukemia.

1 reference

12 December 2020

Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules.

1 reference

12 December 2020

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.

1 reference

12 December 2020

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

12 December 2020

Clinical use of rapamycin in renal allograft recipients identifies its relevant toxicity profile and raises unsolved questions: a Single-Center experience

1 reference

12 December 2020

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

1 reference

12 December 2020

P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation.

1 reference

12 December 2020

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

1 reference

12 December 2020

Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units

1 reference

12 December 2020

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

1 reference

12 December 2020

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

1 reference

12 December 2020

Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells

1 reference

12 December 2020

The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate

1 reference

12 December 2020

Cross‐resistance of imatinib mesylate and 17‐aag in imatinib‐resistant cells that overexpress bcr‐abl

1 reference

12 December 2020

A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.

1 reference

12 December 2020

Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.

1 reference

12 December 2020

Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells

1 reference

12 December 2020

BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity

1 reference

12 December 2020

1 reference

12 December 2020

BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death.

1 reference

12 December 2020

Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts

1 reference

12 December 2020

Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes).

1 reference

12 December 2020

Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide

1 reference

12 December 2020

Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia

1 reference

12 December 2020

CRM1 is responsible for intracellular transport mediated by the nuclear export signal

1 reference

12 December 2020

Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase

1 reference

12 December 2020

Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.

1 reference

12 December 2020

Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells

1 reference

12 December 2020

Roots of clinical resistance to STI-571 cancer therapy

1 reference

12 December 2020

Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.

1 reference

12 December 2020

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

12 December 2020

Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148

1 reference

12 December 2020

The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome

1 reference

12 December 2020

A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation

1 reference

12 December 2020

Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.

1 reference

12 December 2020

In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia

1 reference

12 December 2020

P-glycoprotein in acute nonlymphoblastic leukemia and in the blastic crisis of myeloid leukemia.

1 reference

12 December 2020

Specific inhibition of bcr-abl gene expression by small interfering RNA.

1 reference

12 December 2020

Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor

1 reference

12 December 2020

Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.

1 reference

12 December 2020

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

1 reference

12 December 2020

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

1 reference

12 December 2020

Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.

1 reference

12 December 2020

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours

1 reference

12 December 2020

In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines

1 reference

12 December 2020

A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.

1 reference

12 December 2020

Induction of apoptosis by a dominant negative H-RAS mutant (116Y) in K562 cells

1 reference

12 December 2020

Clonal dominance of chronic myelogenous leukemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastase

1 reference

12 December 2020

The proteasome: a novel target for cancer chemotherapy

1 reference

12 December 2020

Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase

1 reference

12 December 2020

BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells

1 reference

12 December 2020

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

1 reference

12 December 2020

Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia

1 reference

12 December 2020

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

12 December 2020

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

12 December 2020

Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning

1 reference

12 December 2020

The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells

1 reference

12 December 2020

How proteolysis drives the cell cycle

1 reference

12 December 2020

Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation

1 reference

12 December 2020

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

12 December 2020

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

12 December 2020

A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo

1 reference

12 December 2020

Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro

1 reference

12 December 2020

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1 reference

12 December 2020

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

1 reference

12 December 2020

Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines

1 reference

12 December 2020

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

12 December 2020

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

1 reference

12 December 2020

Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase

1 reference

12 December 2020

Histone deacetylases, transcriptional control, and cancer

1 reference

12 December 2020

The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products

1 reference

12 December 2020

BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration

1 reference

12 December 2020

Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells.

1 reference

12 December 2020

Identification and characterization of a new member of the TNF family that induces apoptosis

1 reference

12 December 2020

Ancient pathways programmed by small RNAs

1 reference

12 December 2020

Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia

1 reference

12 December 2020

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

12 December 2020

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

12 December 2020

Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

1 reference

12 December 2020

Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1

1 reference

12 December 2020

STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells

1 reference

12 December 2020

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

1 reference

12 December 2020

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

1 reference

12 December 2020

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

1 reference

12 December 2020

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

12 December 2020

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

12 December 2020

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

12 December 2020

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

12 December 2020

HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates

1 reference

12 December 2020

Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients

1 reference

12 December 2020

Neutrophil elastase enzymatically antagonizes the in vitro action of G-CSF: implications for the regulation of granulopoiesis

1 reference

12 December 2020

An antagonist decoy receptor and a death domain-containing receptor for TRAIL

1 reference

12 December 2020

P210 Bcr-Abl interacts with the interleukin-3 beta c subunit and constitutively activates Jak2

1 reference

12 December 2020

Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro

1 reference

12 December 2020

Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses

1 reference

12 December 2020

Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment.

1 reference

12 December 2020

Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.

1 reference

12 December 2020

Infrequent ras activation in chronic myelogenous leukemia (CML): activating 61st codon mutation in the CML-derived cell line, IM-9.

1 reference

12 December 2020

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

1 reference

12 December 2020

CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs

1 reference

12 December 2020

An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias

1 reference

12 December 2020

Phase I trial of elactocin

1 reference

12 December 2020

Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

1 reference

12 December 2020

Oncogene inactivation in a mouse model

1 reference

12 December 2020

Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia

1 reference

12 December 2020

Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells

1 reference

12 December 2020

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

12 December 2020

Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.

1 reference

12 December 2020

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

12 December 2020

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

1 reference

12 December 2020

Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia

1 reference

12 December 2020

Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.

1 reference

12 December 2020

Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors

1 reference

12 December 2020

Role for a bidentate ribonuclease in the initiation step of RNA interference

1 reference

12 December 2020

CRM1 is an export receptor for leucine-rich nuclear export signals

1 reference

12 December 2020

Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro

1 reference

12 December 2020

A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan

1 reference

12 December 2020

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

12 December 2020

The Jak-Stat pathway in normal and perturbed hematopoiesis

1 reference

12 December 2020

Expression of the multidrug transporter, P-glycoprotein, in chronic myelogenous leukaemia cells in blast crisis.

1 reference

12 December 2020

The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy

1 reference

12 December 2020

Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia

1 reference

12 December 2020

The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate

1 reference

12 December 2020

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

1 reference

12 December 2020

Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors

1 reference

12 December 2020

Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia

1 reference

12 December 2020

Identifiers

DOI

10.1532/IJH97.04032

1 reference

Dimensions Publication ID

10 August 2017

1021122825

0 references

1 reference